THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Drug development is evolving—shifting from small-molecule drugs (under 500 molecular weight) to larger (above 1,000), more complex compounds—designed to interact with biological pathways more precisely. Therapeutics like peptides and GLP-1 receptor agonists offer enhanced efficacy and target specificity but bring formulation challenges due to their size, fragility and poor oral bioavailability. These complexities demand advanced delivery systems and specialized handling. As a vertically integrated contract development and manufacturing organization (CDMO), Laviana Pharma navigates this complexity. By emphasizing early-stage formulation testing, Laviana helps uncover potential stability and delivery issues early, reducing downstream risks and accelerating the path to clinical success. Its scientific rigor and integrated capabilities make it a vital partner for companies bringing next-generation therapeutics to market. Speed and proximity have become Laviana’s key advantages. It has a specialized formulation laboratory in the U.S. designed specifically for the early-phase development of high-molecular-weight drug candidates. Working locally with U.S. clients means faster decisions, real-time adjustments and shorter timelines. Over the past 20 years, Laviana has helped develop hundreds of candidates and contributed to the successful launch of more than 30 drugs. Some of its early-stage collaborations have led to biotech breakthroughs later acquired by major pharmaceutical firms, an indicator of Laviana’s quiet but critical role in drug development success stories. Starting as a small CRO, Laviana quickly moved on to establishing its own pilot plant. After the R&D and manufacturing sites moved to their new locations, the upgrades Laviana received provided an advantage in equipment and capacity. Not only is Laviana able to do hydrogenation up to 2000 L, but the new trending high potency capability has also been recently added to Laviana’s portfolio. With a manufacturing capacity of up to 6300L and a team of more than 100 scientists, Laviana serves some of the most reputable pharmaceutical companies in the world. “Our role is to make drug development faster,” says Wenting Chen, co-founder and CEO. “Having early-stage development capabilities close to home with our hybrid supply chain strategy proves vital during emergencies like the pandemic when global supply chains get severely disrupted.” This strategy balances the reliability of local collaboration with the efficiency of global infrastructure. Along with the U.S.-based formulation lab, Laviana brings the globally distributed R&D and manufacturing network to advance programs from early development through commercialization. In Cangzhou, China, Laviana manages GMP manufacturing and the scale-up of high-potency APIs, where attention to regulatory compliance and technical detail is non-negotiable. Across the country in Beijing, the process development team uses AI-assisted retrosynthesis not as a buzzword, but as a practical tool, reworking complex synthesis routes to improve yields and cut down production time. Laviana’s fully automated facility in China is at the core of this integration, designed to support projects from early-stage research to late-phase clinical trials and commercial readiness.
Atrue drying specialist, Italvacuum goes beyond merely providing innovative equipment and offers an end-to-end service to deliver bespoke solutions that match the distinct ingredient specifications and regulatory mandates of modern day pharmaceutical, fine chemical and chemical organisations. With 85 years of industry presence (1939 -2024), the company is a well known vacuum drying partner that closely collaborates with clients throughout the pilot testing, large scale development, engineering, installation and commissioning processes to ensure the establishment of a genuinely game-changing drying process. Since the beginning, Italvacuum has been a quality-driven company that consistently prioritises holistic customer service, including delivery of spare parts and deployment of dedicated onsite technicians for prompt issue mitigation. With a consolidated portfolio of industrial vacuum piston pumps and vacuum dryers, the company focuses on building a robust drying process built on a foundation of cutting-edge components and fast and reliable customer support. It also emphasises continuous improvement, constantly revamping machines, extending timely support and updating configurations to stay on top of every emerging pharmaceutical application. Furio Zedde, Business Development Manager, and Partner of Italvacuum, highlights its dedication to quality, stating, “We ensure compliance with prominent industry standards like ISO 9001, FDA, the AMSE code and relevant local certifications to achieve seamless and timely distribution of machine components worldwide.” During pilot tests, the company prioritises network and system confidentiality in accordance with relevant data governance and privacy regulations. Be it chemistry, mechanics, process optimisation or technology implementations, Italvacuum can customise machines for diverse vacuum drying-based materials, all while adapting to the latest regulatory changes and automation advancements. This investment in bespoke software incorporates customer insights to serve as the ‘brain’ of a client’s drying machinery. Italvacuum also integrates products with existing networks, distributed control systems (DCS) and production plants to enable complete control across diverse settings. With a 75-strong workforce, the company embraces agility and flexibility in providing service quotations.
Today, drug safety is a strategic imperative, not just a regulatory checkbox. As products move from development to market, the pressure on safety teams never lets up. In early clinical trials, safety signals are scarce but nuanced, requiring deep analysis and rapid response. Post-approval, the landscape shifts: data volumes surge, global regulations diverge, and consistency becomes an uphill battle. Turning pharmacovigilance (PV) from a reactive function into a strategic advantage has become a competitive necessity. Qinecsa enables that transformation. With a singular focus on drug safety, it combines advanced technologies with expert human insight to help manage complexity, ensure compliance, and drive better outcomes across every stage of the product lifecycle. The company offers an integrated technology platform that spans the full safety lifecycle, from case intake and processing to regulatory reporting, safety assessment, and signal detection. Unlike rigid, monolithic systems, Qinecsa’s best-of-breed approach allows clients to mix and match the components that best fit their unique needs. Three Solutions, One Purpose Qinecsa has developed three core technology solutions to support the broad spectrum of PV operations. The Reportum platform enables efficient management of both digital and analogue case reports, including initial and follow-up submissions from diverse global sources and in multiple languages. HaloPV, Qinecsa’s comprehensive drug safety system, oversees all aspects of multivigilance by covering both operational and scientific functions to ensure compliance and quality across the safety ecosystem. Complementing these is the Vigilance Workbench, which supports the end-to-end signal management process by enabling structured tracking, prioritisation, and scientific assessment of emerging safety signals. Together, these interlocking solutions empower pharmaceutical companies to scale their PV capabilities while maintaining a balance between operational efficiency and scientific depth, regardless of size, geography, or stage in the product lifecycle. “We offer our platform as a fully outsourced PV solution or as a standalone SaaS product, giving clients the flexibility to choose the model that best aligns with their goals and resources,” says Adam Sherlock, CEO.
Tomasz Nawrocki, Pharmaceutical Supply Chain Service Department Director/ CEO Synoptis Industrial, Grupa NEUCA
Marianthi Psacha, Global Head of Cell and & Gene Therapy, Santen
Susan K. Maue, Managing Director, US and Puerto Rico, PharmaLex
Max Brescia, Vice President Contract Manufacturing, AbbVie
Ivanna M. Rosendal, Global Head of Digitalization, Ascendis Pharma
Regulatory Tech transforms pharmaceutical compliance in Europe by leveraging AI, blockchain, and NLP for efficiency, transparency, and cost reduction. It ensures adherence to evolving regulations while enhancing drug quality, safety, an
Telemedicine has experienced exponential growth in Europe, driven by technological advancements, increasing healthcare demands, and the need for greater accessibility.
Breaking Boundaries in Pharma
One key area of innovation is pharmaceutical sterilization. Sterilization solutions are becoming more sophisticated, with advancements in steam, dry heat, and chemical techniques that ensure the safety and efficacy of drugs. These technologies are essential in preserving the integrity of pharmaceutical products throughout the manufacturing process.
Equally important are pharmaceutical vacuum pumps, which play a critical role in processes such as filtration, drying and packaging. To meet industry demands, manufacturers are adopting energy-efficient, state-of-the-art vacuum pump systems to ensure reliable performance, maintain consistent product quality and optimize production flow.
As companies navigate increasing regulatory complexities and operational challenges, life sciences consulting services have become indispensable. Experts in this field are helping firms streamline operations, optimize production processes and expand market access, all while ensuring compliance with stringent regulations.
In addition, Contract Manufacturing Organizations (CMO) have become essential partners in the pharmaceutical sector. By leveraging advanced technologies, CMOs offer scalable, cost-effective production solutions, ensuring consistent quality and operational flexibility while meeting the industry’s evolving needs.
In this edition of PharmaTech Outlook Europe, we feature the leading companies driving innovations in pharmaceutical sterilization, vacuum pumps, consulting services and contract manufacturing in Europe. These companies are setting new benchmarks in pharma safety, quality and operational excellence.
We also bring you expert perspectives on the key drivers behind the success of pharmaceutical innovation, including breakthroughs in research, regulatory compliance and the adoption of cutting-edge technologies. Rauno Hoffmann, global head of corporate compliance management at Novartis, underscores the importance of creating custom methods to measure compliance program effectiveness and demonstrate organizational risk reduction. Ozgur Akbulut, director at Takeda, highlights that pharma companies expect CMOs and CDMOs to implement robust continuous improvement strategies, mainly when producing complex treatments like oncology drugs and vaccines.
As the pharmaceutical and life sciences sectors evolve, integrated solutions across compliance, manufacturing and supply chains are shaping the future. We invite you to explore the innovations and expert insights shared in this edition and stay ahead in the fast-evolving pharma landscape.
